FDA-approved Brain & sleep

Trofinetide

Also written as DAYBUE and DAYBUE STIX

Trofinetide is an IGF-1-derived tripeptide analog. It is filed in this library under brain & sleep, a navigation topic rather than a statement of where it acts. As a regulatory matter it has at least one product approved by the FDA. It is also written as DAYBUE and DAYBUE STIX.

Regulatory status

Trofinetide has an FDA-approved product on the U.S. market, marketed as Daybue under application NDA217026.

The current label is held by Acadia Pharmaceuticals Inc.

From the FDA label

What Trofinetide is approved to treat

and DAYBUE STIX are indicated for the treatment of Rett syndrome in adults and pediatric patients 2 years of age and older.Quoted from the FDA-approved prescribing information

The evidence

What has actually been published

One source on Trofinetide, resolved to its journal of record. The title is listed so you can judge the evidence rather than take a summary on trust.

Nearby

Other peptides acting on brain & sleep

Not sure what applies to you?

A 60-second questionnaire, reviewed by a U.S.-licensed physician.

Find my protocol

Educational reference only. This page explains what has been published about Trofinetide. It is not medical advice, it is not a diagnosis, and it carries no dosing information of any kind. OPTML does not offer or supply this compound unless a product page on this site says otherwise.

Treatment decisions are made by a licensed physician after an individual evaluation. Compounded preparations are not FDA-approved or evaluated by the FDA for safety, effectiveness, or quality. Individual results vary.

All 150 peptides